Background: Lecanemab is the first anti-amyloid monoclonal antibody to receive full approval in the US for early Alzheimer’s Disease (AD). Methods: Using open administrative claims from the PurpleLab (6Jan2023–1Aug2024) database, patients receiving ≥1 lecanemab and with continuous clinical activity ≥6 months prior to the first lecanemab infusion were included. The follow-up period ran from the first lecanemab administration to the latest clinical activity. Treatment gap was calculated as the number of days without lecanemab supply between consecutive infusions. Results: A total of 2,840 patients were included. Mean observation period was 130.7 days. Mean age was 75.4 (SD 6.2) years, and 54.8% were female. Most prescribers were neurologists (82.0%). Within 30 days before lecanemab initiation, 77.0% of patients had AD diagnosis, and 32.1% had mild cognitive impairment diagnosis. During lecanemab treatment, 27.2% of patients received cholinesterase inhibitors and 15.5% memantine. Among patients with ≥2 lecanemab infusions, average number of administrations per month was 1.9 (SD 0.4), 17.2 (SD 7.9) days apart; 9.9% had a treatment gap of ≥90 days, including those who discontinued or continuing beyond the gap, and 2.5% of patients experienced a treatment interruption with ≥90 days gap. Conclusions: Real-world use of lecanemab appears to follow FDA-approved prescribing information with high adherence.